# EDGAR Filing Document

**Accession Number:** 0001001233
**File Stem:** 0001193125-25-177017
**Filing Date:** 2025-8
**Character Count:** 21378
**Document Hash:** 8f088f55f96cf144edd7de877afb8cb6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-177017.hdr.sgml**: 20250808

**ACCESSION NUMBER**: 0001193125-25-177017

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250808

**DATE AS OF CHANGE**: 20250808

**EFFECTIVENESS DATE**: 20250808

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SANGAMO THERAPEUTICS, INC
- **CENTRAL INDEX KEY:** 0001001233
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 680359556
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289433
- **FILM NUMBER:** 251198824

**BUSINESS ADDRESS:**
- **STREET 1:** 501 CANAL BLVD.
- **CITY:** RICHMOND
- **STATE:** CA
- **ZIP:** 94084
- **BUSINESS PHONE:** 5109706000

**MAIL ADDRESS:**
- **STREET 1:** 501 CANAL BLVD.
- **CITY:** RICHMOND
- **STATE:** CA
- **ZIP:** 94084

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SANGAMO BIOSCIENCES INC
- **DATE OF NAME CHANGE:** 20000208

**As filed with the Securities and Exchange Commission on August 8, 2025** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## SANGAMO THERAPEUTICS, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **68-0359556** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **501 Canal Blvd.**<br> **Richmond, California** | **94084** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Amended and Restated Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan** 

**(Full Title of Plans)** 

**Alexander D. Macrae** 

**President and Chief Executive Officer** 

**Sangamo Therapeutics, Inc.** 

**501 Canal Blvd.** 

**Richmond, California 94084** 

**(510) 970-6000** 

**(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)** 

***Copies to:***

---

| | |
|:---|:---|
| **Scott B. Willoughby**<br> **Chief Legal Officer and Corporate Secretary**<br> **Sangamo Therapeutics, Inc.**<br> **501 Canal Blvd.**<br> **Richmond, California 94804**<br> **(510) 970-6000** | **Chadwick L. Mills**<br> **Courtney M.W. Tygesson**<br> **Cooley LLP**<br> **3 Embarcadero Center, 20th Floor**<br> **San Francisco, California 94111**<br> **(415) 693-2000** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☒ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

This Registration Statement on Form S-8 is being filed by Sangamo Therapeutics, Inc. (the "Registrant") with the Securities and Exchange Commission (the "Commission") for the purpose of registering an additional 14,000,000 shares of the Registrant's common stock, par value $0.01 per share (the "Common Stock"), to be issued pursuant to the Registrant's Amended and Restated 2018 Equity Incentive Plan (the "2018 Plan"). The Registrant previously registered (i) 19,131,725 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant's registration statement on [Form S-8](http://www.sec.gov/Archives/edgar/data/1001233/000119312518189435/d603403ds8.htm) (File No. 333-225552) filed with the Commission on June 11, 2018 (the "2018 Form S-8"), (ii) 9,900,000 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant's registration statement on [Form S-8](http://www.sec.gov/Archives/edgar/data/1001233/000119312520210798/d24713ds8.htm) (File No. 333-241033) filed with the Commission on August 5, 2020 (the "2020 Form S-8"), (iii) 7,900,000 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant's registration statement on [Form S-8](http://www.sec.gov/Archives/edgar/data/1001233/000119312523045598/d469019ds8.htm) (File No. 333-269925) filed with the Commission on February 23, 2023 (the "February 2023 Form S-8"), (iv) 10,000,000 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant's registration statement on [Form S-8](http://www.sec.gov/Archives/edgar/data/1001233/000119312523206301/d499172ds8.htm) (File No. 333-273805) filed with the Commission on August 8, 2023 (the "August 2023 Form S-8"), and (v) 11,000,000 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant's registration statement on [Form S-8](http://www.sec.gov/Archives/edgar/data/1001233/000114036124046239/ny20037443x2_s8.htm) (File No. 333-283180) filed with the Commission on November 12, 2024 (together with the 2018 Form S-8, the 2020 Form S-8, the February 2023 Form S-8 and the August 2023 Form S-8, the "Prior Registration Statements"). This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E of Form S-8. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated by reference herein.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3.** **Incorporation of Documents by Reference.** <br>

The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registrant's annual report on Form 10-K for the year ended
December 31, 2024, which was filed with the Commission on [March 17, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001001233/000162828025013088/sgmo-20241231.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the information specifically incorporated by reference into the Registrant's annual report on Form 10-K for the year ended December 31, 2024 from the Registrant's definitive proxy statement on Schedule 14A, which was filed with the SEC on [April 30, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001001233/000162828025020773/sgmo-20250429.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registrant's quarterly reports on Form 10-Q for the quarters
ended March 31, 2025 and June 30, 2025, which were filed with the Commission on [May 12, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001001233/000162828025024650/sgmo-20250331.htm) and [August 7, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1001233/000162828025038860/sgmo-20250630.htm) , respectively;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registrant's current reports on Form 8-K, which were filed with
the Commission on [February 6, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001001233/000162828025004197/sgmo-20250206.htm) , [May 6, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001001233/000162828025022664/sgmo-20250430.htm) , [May 13, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001001233/000114036125018697/ny20048472x3_8k.htm) , [June 16, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001001233/000162828025031559/sgmo-20250612.htm) and [June 24, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001001233/000162828025032748/sgmo-20250624.htm) ; and

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the description of the Common Stock contained in the Registrant's registration statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1001233/000095014900000735/0000950149-00-000735.txt) , which was filed with the Commission on March 
31, 2000, including all amendments and reports filed for the purpose of updating such description, including [Exhibit 4.1](http://www.sec.gov/Archives/edgar/data/1001233/000162828025013088/sgmo-20241231xex41.htm) of the Registrant's
annual report on Form 10-K for the year ended December 31, 2024.

All reports and other documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of filing such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

**Item 8.** **Exhibits.** <br>

**<u>Exhibit Index</u>**

---

| | |
|:---|:---|
| Exhibit<br>No. | Description |
| 3.1 | [Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Registrant's Current Report on Form 8-K filed June 2, 2023).](http://www.sec.gov/Archives/edgar/data/1001233/000162828023020692/sgmo-20230602xex33.htm) |
| 3.2 | [Certificate of Amendment of the Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed June 5, 2024).](http://www.sec.gov/Archives/edgar/data/1001233/000162828024026903/sgmo-20240605xex31.htm) |
| 3.3 | [Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed December 19, 2022).](http://www.sec.gov/Archives/edgar/data/1001233/000162828022032209/sgmo-20221219xxex31fifth.htm) |
| 5.1 | [Opinion of Cooley LLP.](d933616dex51.htm) |
| 23.1 | [Consent of Independent Registered Public Accounting Firm.](d933616dex231.htm) |
| 23.2 | [Consent of Cooley LLP (included in Exhibit No. 5.1).](d933616dex51.htm) |
| 24.1 | [Power of Attorney (included on signature page to this Registration Statement).](d933616ds8.htm#sig) |
| 99.1 | [Amended and Restated 2018 Equity Incentive Plan of Sangamo Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed June 16, 2025)](http://www.sec.gov/Archives/edgar/data/1001233/000162828025031559/ex-101amendedandrestated20.htm) |
| 107 | [Filing Fee Table](d933616dexfilingfees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Richmond, State of California, on August 8, 2025.

---

| | |
|:---|:---|
| **SANGAMO THERAPEUTICS, INC.** | **SANGAMO THERAPEUTICS, INC.** |
| By: | /s/ Alexander D. Macrae |
|  Name: | Alexander D. Macrae, M.B., Ch.B., Ph.D. |
|  Title: | President and Chief Executive Officer |

---

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Alexander D. Macrae, Prathyusha Duraibabu and Scott Willoughby, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution and resubstitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| Signature | Title | Date |
| /s/ Alexander D. Macrae<br> Alexander D. Macrae, M.B., Ch.B., Ph.D. | President, Chief Executive Officer and Director<br>(Principal Executive Officer) | August 8, 2025 |
| /s/ Prathyusha Duraibabu<br> Prathyusha Duraibabu | Senior Vice President and Chief Financial Officer<br>(Principal Financial Officer and Principal Accounting Officer) | August 8, 2025 |
| /s/ H. Stewart Parker<br> H. Stewart Parker | Chair of the Board | August 8, 2025 |
| /s/ Courtney Beers<br> Courtney Beers, Ph.D. | Director | August 8, 2025 |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Robert F. Carey<br> Robert F. Carey | Director | August 8, 2025 |
| /s/ Kenneth J. Hillan<br> Kenneth J. Hillan, M.B., Ch.B. | Director | August 8, 2025 |
| /s/ Margaret A. Horn<br> Margaret A. Horn, J.D. | Director | August 8, 2025 |
| /s/ John H. Markels<br> John H. Markels, Ph.D. | Director | August 8, 2025 |
| /s/ James R. Meyers<br> James R. Meyers | Director | August 8, 2025 |
| /s/ Karen L. Smith<br> Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M. | Director | August 8, 2025 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g933616g0807072735907.jpg)

Courtney Tygesson

+1 312 881 6680

ctygesson@cooley.com

August 8, 2025

Sangamo Therapeutics, Inc.

501 Canal Blvd.

Richmond, California 94804

Ladies and Gentlemen:

We have acted as counsel to Sangamo Therapeutics, Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a registration statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering of up to 14,000,000 shares of its common stock, par value $0.01 per share (the "***Shares***"), pursuant to the Company's Amended and Restated 2018 Equity Incentive Plan (the "***Plan***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and related prospectus, (b) the Company's certificate of incorporation and bylaws, each as currently in effect, (c) the Plan and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures; the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, the Registration Statement and related prospectus, will be validly issued, fully paid and nonassessable (except as to Shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Cooley LLP 110 N. Wacker Drive, Suite 4200 Chicago, IL 60606-1511

t: (312) 881-6500 f: (312) 881-6598 cooley.com

------

![LOGO](g933616g0807072735907.jpg)

August 8, 2025 Page Two

---

| | |
|:---|:---|
|  Sincerely, | Sincerely, |
|  Cooley LLP | Cooley LLP |
| By: | /s/ Courtney Tygesson |
|  | Courtney Tygesson |

---

Cooley LLP 110 N. Wacker Drive, Suite 4200 Chicago, IL 60606-1511

t: (312) 881-6500 f: (312) 881-6598 cooley.com

## Exhibit 23.1

**Exhibit 23.1** 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Amended and Restated Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan of our reports dated March 17, 2025, with respect to the consolidated financial statements of Sangamo Therapeutics, Inc., and the effectiveness of internal control over financial reporting of Sangamo Therapeutics, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

---

| | |
|:---|:---|
| San Mateo, California | /s/ Ernst & Young LLP |
| August 7, 2025 |  |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**SANGAMO THERAPEUTICS, INC**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, par value $0.01 per share | Other | 14000000 | $0.54 | $7560000.00 | 0.0001531 | $1157.44 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $7560000.00  |  | $1157.44  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $1157.44  |

---

 **Offering Note** <br>

<sup>1</sup> (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers an indeterminate number of additional shares which may be offered and issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. (2) Covers shares issuable under the Amended and Restated Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan. (3) Pursuant to Rule 457(c) and 457(h)(i) under the Securities Act, the proposed maximum offering price per share and the proposed maximum aggregate offering price are estimated solely for the purpose of calculating the amount of the registration fee and are based on a price of $[ ] per share, which is the average of the high and low prices per share of the Common stock reported on The Nasdaq Capital Market on August 5, 2025.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---